Eli Lilly and Company (NYSE:LLY) Shares Down 1.6% - Here's Why

Key Points

• Foundayo launch: Lilly rolled out its oral GLP‑1 pill Foundayo with broad distribution partnerships (Amazon Pharmacy, GoodRx, WeightWatchers, telehealth) and transparent pricing (about $25/month with coverage or $149/month self‑pay), positioning the drug for rapid patient access and revenue ramp.
• Stock and competitive pressure: Shares slipped down 1.6% to roughly $940 on light volume, as concerns about generic semaglutide in India and intensified competition (including Novo Nordisk pricing/convenience moves and oral competitors) raise near‑term margin and market‑share uncertainty.
• Wall Street and fundamentals: Analysts remain largely positive with several price‑target raises (average target ≈ $1,224.59), supported by beat‑and‑raise quarterly results and FY2026 EPS guidance of 33.5–35.0.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price dropped 1.6% during trading on Friday . The company traded as low as $935.54 and last traded at $939.7910. Approximately 1,951,343 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 3,138,775 shares. The stock had previously closed at $955.19.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly has launched its oral GLP‑1 pill Foundayo (orforglipron) and is rolling it out broadly via LillyDirect, telehealth, retail pharmacies and partners — positioning the drug for fast patient access and revenue ramp; pricing is transparent (from $25/mo with coverage, $149/mo self‑pay). LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships
• Positive Sentiment: Major distribution wins: Amazon Pharmacy will stock Foundayo (kiosks and same‑day delivery) and other partners (GoodRx, WeightWatchers, telehealth platforms) broaden access and could accelerate uptake. Amazon to stock Lilly's new weight-loss pill at US kiosks, offer same-day delivery
• Positive Sentiment: Street support: Morgan Stanley raised its price target to $1,327 and keeps an overweight stance, signaling continued analyst confidence in Lilly’s growth runway. Benzinga: Morgan Stanley price target raise
• Neutral Sentiment: Some analysts remain cautious: Rothschild & Co Redburn nudged its target slightly but maintained a neutral rating, underscoring differing views on near‑term valuation vs execution risk. Rothschild & Co Redburn adjusts price target on Eli Lilly to $880
• Neutral Sentiment: Market commentary highlights Lilly’s strong tirzepatide franchise and industry positioning even as competition intensifies — useful context but not an immediate stock mover by itself. Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader
• Negative Sentiment: Pricing and generic pressure in India: cheaper semaglutide generics are eroding Lilly’s local share (reportedly down from ~61% to ~56%), a preview of potential margin/volume pressure in price‑sensitive markets. Eli Lilly slips as generic weight-loss drugs flood India
• Negative Sentiment: Market‑share and competitive pressure: reports show Lilly’s market share dipping amid an intensifying weight‑loss drug war (pricing moves and oral competitors), creating short‑term uncertainty for sales and pricing power. Eli Lilly’s Market Share Dips as Weight-Loss Drug War Heats Up
• Negative Sentiment: Novo Nordisk’s pricing/convenience moves (higher‑dose Wegovy, lower price points) and broader oral competition increase the risk of margins and market share being contested globally. What Novo Nordisk's higher-dose, lower-priced Wegovy move means

Wall Street Analyst Weigh In

Several research firms recently weighed in on LLY. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Wall Street Zen lowered Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Monday. Bank of America lifted their price target on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a "buy" rating in a research report on Thursday, April 2nd. CICC Research lifted their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research report on Wednesday, February 11th. Finally, Guggenheim dropped their price target on Eli Lilly and Company from $1,168.00 to $1,163.00 and set a "buy" rating on the stock in a research report on Monday, March 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,224.59.

Eli Lilly and Company Stock Down 1.6%

The stock has a 50 day simple moving average of $985.96 and a 200-day simple moving average of $972.98. The firm has a market cap of $887.93 billion, a PE ratio of 40.95, a PEG ratio of 1.11 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm's quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Morgan Stanley raised its stake in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock worth $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Finally, Capital World Investors raised its stake in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.